Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
about
Is GLP-1 a hormone: Whether and When?Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the BlockLocal, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum.Meal-anticipatory glucagon-like peptide-1 secretion in rats.The incretin system and cardiometabolic diseaseEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes.Nonhuman primates and other animal models in diabetes research.The role of incretins in glucose homeostasis and diabetes treatment.The role of gut hormones in glucose homeostasisGLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modificationLipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitorsβ-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channelComparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and MechanismsExenatide can reduce glucose independent of islet hormones or gastric emptying.The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects.Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestionCNS GLP-1 regulation of peripheral glucose homeostasis.Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptidesThe role of dysregulated glucagon secretion in type 2 diabetes.Incretins: their physiology and application in the treatment of diabetes mellitus.Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretiExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.New ways in which GLP-1 can regulate glucose homeostasis.Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice.Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system.Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice.Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice.
P2860
Q26749196-844B6F2C-F680-406E-B1AB-377572B85C90Q26825393-9829857B-A7AB-4098-8679-6ABCD96D6B67Q33184111-80D014F1-3F64-4E11-BA90-1A572C3FDCA5Q33634407-914DA729-5DB7-4048-9A10-7FB86EBC8049Q33776092-084A3D10-FCD1-4A23-BD71-97491D78503AQ33869732-C82A617A-0F7A-4F73-8110-8EEABCDB9C2EQ34286456-EEDBA195-06F9-4D2A-A810-099B3F9DCCD7Q34901533-6080D6EB-A154-46DA-A19B-D9823226885DQ35251016-F7D52823-3F55-408C-95DF-CB9E6BDBCCFEQ35360690-04DB2EFE-9215-4084-BE6E-02B286C1C46CQ35624667-CC44C78B-29F4-444D-A415-6396B8499619Q35680897-79248B27-04D1-4B9F-827E-A1628538E9ABQ35772029-8626C6A6-9A07-4D2F-8E5E-1BEE2322EF38Q36249759-D320DB75-3E7D-4230-A9B0-0218791B643CQ36479829-69A8FA8C-DF20-44C4-9F6A-0A1CD89AB834Q36846123-5DF157B5-6141-484A-9AC0-B8BDB4134CC5Q36902183-2612F163-BF58-46AE-BE8F-52981A4EDB0DQ37031078-037E0C93-A91F-48DF-8BB2-84A71CC2914BQ37061286-A7491861-FC32-41E1-9FE5-489739AFDF27Q37174896-6813A010-8BA4-439E-AC76-249A3B45ABE8Q37212333-0B316FD0-FAB9-4AC3-A8AB-9D7AF830F59DQ37913523-3FA6570A-2299-48E3-8882-0C3F6841E3D9Q38225693-5E6C24F3-7EC7-4A2E-9140-44C6E0BEF385Q38356895-4E3BA34D-D4CC-4C69-8EC9-3C35DFFD5AA0Q39801749-AFC85AD6-38C8-459A-96AA-4EF23A7722C0Q40036350-BB53A88A-6331-42B1-98BB-8CC46A7645A4Q40420025-B582AD04-5E22-4392-845A-4A752F3608F1Q42136958-2836C2BB-3E6C-479A-96EB-BAC6EC68771CQ42492321-C7CA6C6A-EFB4-4910-9003-33B4790190F9Q43638669-03432991-8754-4F1D-B573-5E3D197F62A4Q44665356-23526D66-B9E0-4A80-9CBB-B25D682F51B3Q48183718-84F01CB5-0800-4560-ADFF-AACBF5A5425BQ54068522-39F69F7C-AF8C-4C74-B637-8140C96A76F9
P2860
Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Elimination of the action of g ...... ingestion by healthy baboons.
@en
Elimination of the action of g ...... ingestion by healthy baboons.
@nl
type
label
Elimination of the action of g ...... ingestion by healthy baboons.
@en
Elimination of the action of g ...... ingestion by healthy baboons.
@nl
prefLabel
Elimination of the action of g ...... ingestion by healthy baboons.
@en
Elimination of the action of g ...... ingestion by healthy baboons.
@nl
P2093
P2860
P356
P1476
Elimination of the action of g ...... ingestion by healthy baboons.
@en
P2093
D A D'Alessio
E Laschansky
J W Ensinck
P2860
P304
P356
10.1172/JCI118380
P407
P577
1996-01-01T00:00:00Z